pembrolizumab,lenvatinib
merck,eisai pharmaceutical
['keynote-775', 'lenva', 'pembro', 'gyn']
an exploratory analysis of the phase 3 study 309/keynote-775 trial showed clinically meaningful improvements in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab. #gyncsm #asco22 
Oncology news and insights from leading researchers and cancer centers.